Chinese biotech Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) has entered into a collaboration and licensing agreement with ...
Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...
GlobalData on MSN11d
Innovent and Roche link on lung cancer therapy developmentInnovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a ...
In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...
Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...
Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...
Analyst Jill Wu of CMB International Securities maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), boosting the price ...
Innovent Biologics (HK:1801) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street ...
Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback